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Diabetes is a growing worldwide epidemic and a leading cause of blindness in working-age
people around the world. Diabetic retinopathy (DR) and diabetic macular edema (DME) are
common causes of visual impairment in people with diabetes and often indicate the pres-
ence of diabetes-associated preclinical micro- and macrovascular complications. As such,
patients with DR and DME often display complex, highly comorbid profiles. Several treat-
ments are currently available for the treatment of DME, including anti-vascular endothelial
growth factor (VEGF) agents, which are administered via intravitreal injection. While the
safety profiles of approved ocular anti-VEGF therapies have been reassuring, the high-
risk nature of the DME patient population means that treatment must be carefully consid-
ered and a holistic approach to disease management should be taken. This requires mul-
tidisciplinary, collaborative care involving all relevant specialties to ensure that patients
not only receive prompt treatment for DME but also appropriate consideration is taken
of any systemic comorbidities to evaluate and minimize potentially serious safety issues.
 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
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in the world [1–3]. A key contributing factor to this is inade-
quate glycemic control [4,5]; despite the advent of multiple
new agents to treat hyperglycemia, with lower risk of weight
gain and hypoglycemia than previous treatments, many peo-
ple with diabetes are not meeting their glycemic targets [6,7].
This increases the risk of developing serious comorbidities,
such as cardiovascular disease, stroke, nephropathy, and neu-
ropathy [2,8,9]. However, the comorbidity most feared by peo-
ple with diabetes is diabetic retinopathy (DR) [10,11]. This is
with good reason; not only can untreated DR progress to dia-
betic macular edema (DME), one of the most common causes
of visual impairment in people with diabetes [12,13], but it
often heralds the presence of preclinical micro- and
macrovascular complications [4,14–16]. Indeed, the presence
of DME is strongly predictive of cardiovascular disease and
stroke [17]. Among individuals with diabetes, vision loss is
one of the most feared complications [10,11]. Vision is vital
for people with diabetes to retain their independence and
manage their disease by being able to see well enough to pre-
pare insulin for injection, check blood sugar levels, and take
medications [18].
People with diabetes are often primarily under the care of
their primary care physician and/or diabetologist [19,20]. Sepa-
rately, patientsmayhave theirdiseasemonitoredat retinal pho-
tography clinics or by other specialists [20], such as
nephrologists or podiatrists. The primary care physician is cen-
tral in coordinating this care, and in terms of eye care, is respon-
sible for ensuring screening checks and prompt referral to an
ophthalmologist, if indicated [21]. However, a recent review by
Seidu et al. concluded that, when implementing diabetes care
programs, stand-alone interventions, such as primary care
physician or nurse education alone, should be avoided [22]. As
well as being expensive to deliver, the outcomes were found to
be less effective in improving glycemic control than implemen-
tation ofmultifaceted professional interventions onmultidisci-
plinary teams [22]. Continuous quality improvement programs
have been essential for ensuring people with diabetes receive
adequate and timely care, including the detection of previously
undiagnosed comorbidities and complications [23]. Manage-
ment of risk factors for DR and DME can also help to reducethe risk for other comorbidities associated with diabetes [5,24].
Furthermore, effective treatments for DME that can attenuate
and even reverse progression of the disease process are now
available [25–28].2. Pathogenesis of DME
The pathogenesis of DME is multifaceted, complex and not
yet fully elucidated [29]. Nevertheless, sustained hyper-
glycemia and subsequent damage to the microvasculature
and breakdown of the blood–retina barrier are thought to be
key processes in the development of the disease [29].
Chronic hyperglycemia is thought to promote DME devel-
opment through oxidative damage, protein kinase C activa-
tion and the release of advanced glycation end products
[29]. Downstream of these changes, vasoconstriction can lead
to altered blood flow to the retina and hypoxia [29]. As a com-
pensatory mechanism, expression of vascular endothelial
growth factor (VEGF) is upregulated, contributing to disrup-
tion of the blood–retinal barrier by increasing vascular perme-
ability [29]. An accumulation of fluid within the layers of the
macular (macular edema) subsequently results from the
increased, abnormal flow of fluid into the neurosensory retina
[29].3. Clinical features of DME
Clinical features frequently observed in DME include retinal
thickening, cystoid macular edema, serous retinal detach-
ment, vitreomacular traction, and hard exudates [29]. The
term ‘clinically significant macular edema’ (CSME) is used in
cases where retinal thickening is present at or within
500 lm of the center of the macula or is of at least 1 disk area
in size andwithin 1 disk diameter of the center of the macula,
and/or hard exudates are present within 500 lm of the center
of the macula with adjacent retinal thickening [29,30]. It is the
presence of these features that can cause gradual reduction in
visual acuity (VA) [31,32]. CSME is further classified as focal
and diffuse DME, based on observations made during clinical
investigation [29].
Fig. 1 – Fundus photograph (A) and corresponding optical coherence tomography image (B) of a healthy eye. Fundus
photograph (C) and corresponding optical coherence tomography image (D) of an eye with diabetic macular edema.
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In addition to standard fundus photography, used to identify
retinal abnormalities (Fig. 1), and best-corrected visual acuity
(BCVA) measurement through letter chart testing, several
imaging techniques can be used to help to identify and mea-
sure the clinical features of DME [3]. Optical coherence
tomography can generate a three-dimensional image by shin-
ing infrared light on to the retina and analyzing the scatter
pattern (Fig. 1) [29,33]. This can help to identify changes in
the retina, including retinal thickening, macular edema, and
serous retinal detachment [29]. Leakage from blood vessels
in the retina can be visualized by injecting fluorescent dye
into a patient’s bloodstream prior to photographing; this tech-
nique is known as fluorescein angiography (FA) [3,29], and is
employed to classify focal and diffuse CSME [29]. Focal CSME
is diagnosed when distinct points of hyperfluorescence, as a
result of microaneurysm leakage, are observed with FA,
whereas diffuse CSME is diagnosed if general areas of
intraretinal leakage from a retinal capillary bed are observed
[29].
5. Available treatment options for DME
A number of therapeutic options are available for the treat-
ment of visual impairment due to DME. For the last three dec-
ades, the main treatment for DME has been laser therapy [34].
Focal laser therapy is thought to seal microaneurysms and thus
help to prevent leakage in cases of focal DME [35]. Grid laser
therapy is thought to increase oxygen availability to areas of
hypoxia by reducing demands elsewhere, and subsequently
decrease vasoconstriction [35]. This, in turn, reduces the total
area of abnormal leakage, helping to resolve macular edema
and re-establish the retinal pigment epithelium [35]. Laser
therapy has been successful for stabilizing vision, that is, pre-
venting any further vision loss; however, recovery of full VA
following laser therapy is rare [30,34].Corticosteroid therapy is able to inhibit many of the
processes known to be involved in the progression of DME,
through anti-inflammatory properties [36] and VEGF
inhibition [37]. It is therefore not surprising that intravitreal
corticosteroid injections have been shown to be an effective
therapy for DME [27,34,38]. Long-acting corticosteroid
implants are also available, which have the added benefit of
reducing the number and frequency of injections [29,34].
However, an increased chance of pathologic intraocular pres-
sure elevation and cataracts must be taken into account when
considering these therapies [28,34,38].
More recently, two anti-VEGF agents have been approved
for the treatment of DME [39,40]. Clinical trials in patients
with DME have repeatedly shown that anti-VEGF therapy
not only stabilizes but also restores vision in a substantial
proportion of those treated [25,26].
6. Anti-VEGF agents – mode of action and
rationale for use
The human VEGF family comprises a number of related pro-
teins, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and pla-
cental growth factor (PlGF) [41]. All are able to influence
angiogenesis and have key roles in vascular formation and
maintenance [41,42]. The normal circulating level of VEGF
has protective actions, including maintenance of angiogene-
sis and endothelial cell integrity [42]. However, people with
diabetes may experience increased vasoconstriction and cap-
illary loss within the retina causing hypoxia, upregulation of
VEGF, and subsequent increased vascular permeability, one
of the key mediators of DME [29]. The effects of VEGF are
actioned via specific VEGF receptors (VEGFRs) [41], with each
having a separate purpose within a particular tissue [43].
Recently, it has been demonstrated that a single cell can dif-
ferentially express multiple receptors on different surfaces,
thereby generating a particular response dependent not only
on the VEGF that is presented, but also the origin of the VEGF
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VEGFR-1 (fms-related tyrosine kinase 1; Flt-1) on the luminal
side, which has cytoprotective properties mediated through
Akt [44]. The same stimulus presented on the neural side
interacts with VEGFR-2 (kinase insert domain receptor; KDR)
and stimulates intracellular p38, triggering hyperpermeability
[44]. This provides an attractive intravitreal pathophysiologic
target that may help to reduce vascular permeability and
macular edema in the eye.
Given the important role that VEGF plays in normal vascu-
lar homeostasis [41,42], there is particular interest in determin-
ing whether intravitreal anti-VEGF injections could have an
impact on circulating VEGF. The potential for systemic safety
effects are particularly relevant in patients with DME, given
their high risk of comorbidities [4,14–16]. Much of the informa-
tion regarding systemic safety originates from the use of
anti-VEGF therapy in oncology services [42]. The role of VEGF
in angiogenesis is necessary to perpetuate tumors [45] and sys-
temic anti-VEGF therapy is widely used as a pre-treatment
prior to curative surgery to improve patient outcomes [46].
Data collated from this usage has given us valuable informa-
tion about the effects of systemic VEGF inhibition on other
organ systems, including compromised wound healing,
increased risk of hypertension and thromboembolic events,
cardiac dysfunction, and renal toxicity [42]. Neurogenesis and
neuroprotection may also be impaired, which could be a
significant problem for someone with diabetes who is already
experiencing neuropathy in some form [47]. In the setting of
a cancer treatment that improves survival rates, the risks
associated with VEGF inhibition are acceptable; however, in
the setting of treating a lifelong chronic condition such as
diabetes, which is known to adversely affect the vasculature
[8], these potential side effects cannot be justified. A greater
understanding of the exact mode of action and pathways
affected therefore becomes necessary.
These observations are of particular interest when consid-
ering the potential systemic exposure of intravitreal anti-
VEGF agents in high-risk patients, such as those with DME. A
recent pooled safety analysis of ranibizumab and aflibercept
in patients with DME (N = 1078) has indicated that patients
with the highest exposure to anti-VEGF therapy (monthly
treatment over 2 years) may have an increased risk for some
systemic adverse events (AEs) compared with sham/laser
treatment arms [48]. Systemic safety warnings for the poten-
tial risk of arterial thromboembolic events (ATEs) are common
to both anti-VEGF agents approved for the treatment of DME
[39,40]; agents that target VEGF and VEGFR share ‘class’ effects
as a result of systemic VEGF inhibition [42,49]. This is an impor-
tant aspect to be taken into account when considering a med-
ication for DME; however, the wealth of anti-VEGF safety data
from clinical trials in DME, summarized below, is reassuring.
7. Anti-VEGFagents used in the treatment of DME
7.1. Ranibizumab (LUCENTIS; Novartis, Basel,
Switzerland/Genentech, South San Francisco, CA, USA/
Roche, Basel, Switzerland) [39]
Ranibizumab is a monoclonal anti-VEGF-A Fab fragment that
was specifically developed for intraocular use [39,50]. Thedesign of the molecule maintains the maximum biologic
activity while localizing the effects to the eye and minimizing
systemic exposure [39,50]. In the eye, ranibizumab inhibits
the action of VEGF-A, decreasing vascular permeability and
edema [39,50].
Several clinical trials have demonstrated the efficacy and
safety profile of ranibizumab in the treatment of patients with
DME. The 12-month, phase III RESTORE study compared rani-
bizumab 0.5 mg monotherapy (n = 116) or combined with
laser (n = 118), with laser alone (n = 111) [51]. Mean change
in BCVA from baseline to Month 12 was significantly greater
with ranibizumab (6.8 ± 8.3 letters; p < 0.0001) and ranibizu-
mab with laser (6.4 ± 11.8 letters; p = 0.0004) than with laser
monotherapy (0.9 ± 11.4 letters) [51]. The initial core study
was extended to assess ranibizumab administered using an
individualized pro re nata (PRN) regimen over 3 years and per-
mitted patients previously receiving laser alone to switch to
ranibizumab 0.5 mg PRN [25,51,52]. The RESTORE extension
studies demonstrated that patients in the ranibizumab
groups maintained their initial BCVA gains through Month
36 and highlighted that early treatment with ranibizumab is
key in reducing vision loss [25,52]. The identical 36-month,
phase III RIDE and RISE studies (N = 759), plus 2-year open-
label extension (N = 500), similarly demonstrated that ranibi-
zumab induced significant, sustained improvements in visual
outcomes [32,49,53].
Importantly, ranibizumab was largely well tolerated in the
RESTORE, RISE and RIDE studies [25,32,49,51–53], and other
studies assessing its use in patients with DME [54,55]. In RISE
and RIDE, rates of systemic side effects were low and similar
across ranibizumab and sham treatment groups: 5.6% and
11.9% of patients in the ranibizumab 0.5 mg group in RISE
and RIDE, respectively, experienced a serious AE potentially
related to inhibition of systemic VEGF, compared with 10.6%
and 9.4% in the sham treatment group over 24 months [32].
Causes of death in RISE and RIDE were consistent with those
commonly observed in patients with advanced diabetes
[32,49,53]. No new ocular or systemic safety findings were
observed following long-term ranibizumab use in the 3-year
RESTORE study and data were consistent with other DME tri-
als and ranibizumab studies in neovascular age-related mac-
ular degeneration and retinal vein occlusion [25]. Real-world
use of ranibizumab is currently being monitored in LUMI-
NOUS (NCT01318941), the largest observational trial in oph-
thalmology [56].
7.2. Aflibercept (EYLEA; Bayer HealthCare, Berlin,
Germany/Regeneron Pharmaceuticals Inc., Tarrytown, NY,
USA) [40]
Aflibercept is a recombinant anti-VEGF-A/VEGF-B/PlGF fusion
protein containing the fragment crystallizable region (Fc) por-
tion of IgG [57]. Aflibercept was initially designed for systemic
oncology therapy (metastatic colon cancer) [58], but is also
licensed for ocular use [40]. The presence of the Fc portion
in aflibercept may permit the molecule to move across the
blood–retina barrier and into the systemic circulation, and
reductions in systemic VEGF levels have previously been
observed following intravitreal aflibercept treatment [59–61].
The efficacy and safety profiles of aflibercept in DME were
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ies (N = 865) [26,62]. Intravitreal aflibercept (2 mg) was associ-
ated with significant BCVA gains from baseline over
100 weeks, compared with laser treatment [26]. Despite the
potential risk of increased systemic exposure [61], incidences
of nonocular AEs in VISTA and VIVID were low and similar
across treatment groups [26]. Rates of cerebrovascular acci-
dent were slightly higher in the aflibercept group (pooled
monthly and bimonthly treatment groups) than the laser con-
trol group (2.2% vs 0.7%, respectively), while incidence of
acute myocardial infarction and acute cardiac failure was
higher in the laser control group than the pooled aflibercept
group (2.1% vs 0.9% and 1.4% vs 0.3%, respectively), and no
clear trend was observed [26]. The incidence of Anti-Platelet
Trialists’ Collaboration criteria-defined ATEs were low and
equivalent across treatment groups [26].
Further studies of aflibercept are ongoing. ENDURANCE-2
(NCT02368756) will examine the need for further aflibercept
treatment in patients after the 3-year VISTA DME endpoint,
and the TADI study (NCT02633852) will evaluate the efficacy
of a treat-and-extend aflibercept regimen as a second-line
treatment for DME.7.3. Bevacizumab (AVASTIN; Genentech/Roche) [63]
Bevacizumab is a full-length anti-VEGF-A monoclonal anti-
body that was developed, and is currently approved, as a sys-
temic therapy for several oncology indications [63].
Bevacizumab is not licensed or manufactured for ophthalmic
indications but the agent is used off-label for the treatment of
retinal disease, including DME [64,65]. As with aflibercept, the
inclusion of the Fc portion in the design of the molecule may
allow bevacizumab to pass from the vitreous into the sys-
temic circulation [61,66]. Reductions in systemic VEGF levels
have been seen after intravitreal bevacizumab treatment
[61,66], as well as therapeutic effects in the fellow untreated
eye [67].8. How can we further improve treatment for
patients with DME?
While anti-VEGF agents have proven efficacy in providing
visual benefits in patients with DME, in order to achieve opti-
mal treatment outcomes, the patient must be considered as a
whole. This requires a collaborative approach that ensures
prompt treatment for the patient’s eye condition as well as
proper consideration of systemic comorbidities and potential
safety issues.
In addition to selecting the right therapy for each
patient, timing of treatment is also important. Because
vision loss with DME generally occurs very gradually
[31,32], early diagnosis offers the opportunity for early
anti-VEGF treatment and the prospect of a more favorable
outcome than if treatment was delayed [25,52]. Regular
and frequent screening helps to identify DME as early as
possible, and timely referral helps to ensure that patients
are treated promptly [21]. Nevertheless, help is still needed
for patients who already have severe DR or DME and are at
risk of losing their vision.Integrating ophthalmologists into multidisciplinary medi-
cal teams that include diabetologists, internists or primary
care physicians as well as specialists in comorbidities may
help [68,69]. An excellent example of the benefit of a multidis-
ciplinary team is the treatment of people who require a hip
replacement following a fall [70]. As most hip fracture
patients are elderly, there are other comorbidities to consider,
so the teams include orthopedic, geriatric, mental health,
bone heath, and falls prevention specialists to assess the best
rehabilitation strategy for the patient [70]. Liaison with pri-
mary care and social services is also essential to ensure the
patient is cared for from inpatient admission through to com-
munity rehabilitation [70,71]. The ultimate aim of engaging
multidisciplinary teams as early as possible is for the patient
to achieve the best possible care and recover quickly whilst
minimizing hospital stay, post-treatment complications, and
cost [71].
Many patients with DME share the same complex, highly
comorbid profile as those with hip fracture; however, collabo-
rations between retinal specialists and other specialists, such
as diabetologists, are currently often limited. Although there
are examples of multidisciplinary teams for diabetes in gen-
eral [72,73], they do not yet extend to cover comorbidities in
an integrated way. An example of a successful, efficient pro-
gram for applying integrated, personalized care to the dia-
betes population is the ‘Chronic Care Model’, developed in
the USA [74]. The model operates on several levels, from
working with governing bodies to reorganize and redefine
healthcare teams to facilitate access to appropriate care in a
coordinated and timely fashion, to educating and encourag-
ing patients in self-management of their condition(s) and
forging links between the healthcare system and the commu-
nity [74]. Evidence of the benefits of applying this model have
included increased rates of eye examinations, improved gly-
cemic control, reduced blood pressure and weight, and better
clinical outcomes overall [74].
Within themultidisciplinary team, each healthcare profes-
sional retains their specialist role, but operates with the aim
of working seamlessly with other specialists, such as through
joint clinics, as well as other departments to link the hospital,
general practice and community. The consultant diabetolo-
gist may take a leadership role within the team, to provide
specialist clinical advice and co-ordinate the team members
[75]. In some cases, implementation of the Chronic Care
Model has caused staff roles to change slightly, to improve
efficiency [74]. In one example, nurses, instead of primary
care physicians, became responsible for performing foot
examinations, and as a result, foot care improved [74].
Development and utilization of patient administration
systems specifically designed to ensure all of the specialist
team members have easy access to data and notes for each
patient, and to improve communication between team mem-
bers, would facilitate more integrated treatment. For exam-
ple, glycemic targets for each individual that are appropriate
to their full clinical picture could be set [74]. Patients may also
benefit from their specialists being aware of the potential side
effects and interactions between treatments prescribed by
their colleagues. Specialists may then be more mindful of
potential systemic side effects and be able to identify them
more quickly. The Medical Archival Retrieval System is one
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that stores laboratory test results, medications, comorbidi-
ties, and patient visit data [74]; information that can poten-
tially help to avoid AEs and unnecessary clinic visits.
Finally, as evidenced with the Chronic Care Model,
patients themselves can also play a large part in their treat-
ment. From the outset, individuals with diabetes and patients
with DR/DME should be encouraged to regularly monitor their
vision at home and be motivated to help themselves manage
their systemic conditions and ensure clinic visit, treatment,
and medication compliance.
9. Conclusions
Although the benefit of anti-VEGF agents for improving VA in
patients with DME is proven, achieving optimal outcomes will
require consideration of the patient as awhole. Using a collab-
orative approach to patient management could help to ensure
early detection and treatment for DME and proper considera-
tion of systemic comorbidities and potential safety issues.
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